Type of non Hodgkin's lymphoma-Follicular lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor

Evaluating outcomes for patients with follicular lymphoma after rituximab maintenance therapy

Posted by on Aug 4, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at long-term outcomes for patients with follicular lymphoma after rituximab (Rituxan) maintenance therapy. This study concluded that rituximab maintenance helped improve long-term survival without disease progression compared to no treatment. Some background Follicular lymphoma (FL) is the second most common type of...

Read More

Evaluating the risk of secondary cancers from infections in patients with non-Hodgkin’s lymphoma

Posted by on Aug 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether there is a link between the type of non-Hodgkin’s lymphoma (NHL) and the development of secondary cancer due to certain infections.  The authors concluded that patients with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphoma (MZL) may be at risk for developing a second type of...

Read More

Evaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients.  Some background Patients with NHL are often treated with targeted therapies....

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).   This study concluded that this combination appears safe and effective for these patients.   Some background Patients...

Read More

Evaluating rituximab maintenance therapy versus observation for follicular lymphoma

Posted by on Apr 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy for patients with follicular lymphoma (FL) after frontline treatment with BR (bendamustine, rituximab). This study concluded that rituximab maintenance is effective for these patients. Some background Chemoimmunotherapy containing rituximab remains the...

Read More

Evaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma

Posted by on Apr 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...

Read More